



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911



NITI Aayog
Government of India

**MedTech
mitra**

Handholding MedTech
innovators for clinical
evaluation, regulatory
facilitation and uptake of
new medical devices,
diagnostics, therapeutics,
and vaccines
A NITI Aayog-ICMR-CDSCO initiative



औषध विभाग
Department of
Pharmaceuticals

**MedTech
mitra | MEDX**
Accelerating MedTech Innovations

9th MedTech Mitra Workshop

Regulatory Pathways, Strategies & Experiential Learning for Development of Therapeutic & Vaccine Technologies

organized by

***ICMR Medical Innovation Public-Private Partnership (MI-PPP) Unit
in collaboration with CDSCO***

*MedTech Mitra -INTENT: facilitating handholding support for clinical studies of
therapeutics and vaccines, and enabling regulatory-compliant clinical development.*



Dr. Rajiv Bahl
Secretary, DHR and DG, ICMR



Dr. Rajeev Singh Raghuvanshi
DCGI, CDSCO



16 October 2026, Friday



10 AM onwards



National Academy of Medical Sciences, New Delhi



**SCAN TO
REGISTER**





icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911



NITI Aayog
Government of India

**MedTech
mitra**

Handholding MedTech
innovators for clinical
evaluation, regulatory
facilitation and uptake of
new medical devices,
diagnostics, therapeutics,
and vaccines
A NITI Aayog-ICMR-CDSCO initiative



औषध विभाग
Department of
Pharmaceuticals

**MedTech
mitra | MEDX**
Accelerating MedTech Innovations

9th MedTech Mitra Workshop

Regulatory Pathways, Strategies & Experiential Learning for Development of Therapeutic & Vaccine Technologies

About workshop

The workshop, under the aegis of **ICMR's Medical Innovations Public-Private Partnership (MI-PPP) Unit**, focuses on regulatory pathways, strategic approaches, and experiential learning to accelerate the development and translation of safe, effective, and regulatory-compliant **therapeutic and vaccine technologies** for wider public use.

Key Topics

- ◆ Regulatory Pathways for Therapeutics & Vaccines in India
- ◆ Regulatory Submission and Compliance for Therapeutics and Vaccines under the NDCT Rules, 2019
- ◆ Preclinical Safety and Efficacy Evaluation of Therapeutics and Vaccines: Key Principles and Regulatory Considerations
- ◆ Generating Clinical Evidence for Therapeutics: Key Considerations for regulatory compliance
- ◆ Medical Innovations Public-Private Partnership (MI-PPP): Enabling Innovators to Navigate the Regulatory Pathway
- ◆ MedTech Mitra: Connecting Innovators to Clinical Trial Networks for Evidence Generation
- ◆ Experiential Learning

**Speakers from
ICMR, CDSCO and INDUSTRY**

Who should attend

- Biomedical Engineers
- Innovators including Start-ups & Academicians
- Scientists/Clinicians & other Healthcare professions
- Regulatory professionals



16 October 2026, Friday



10 AM onwards



SCAN TO REGISTER